Zivo Bioscience, Inc. · OTC:ZIVO
Zivo Bioscience — Non-Deal Roadshow (June 2021)
24 slides from Zivo Bioscience's roadshow presentation, June 2021
Slide 1: Transformative Opportunities in Immune Health & Nutrition
Transformative Opportunities in Immune Health & Nutrition June 2021 ZIVO Bioscience, Inc. | Ticker: ZIVO
Slide 2: Disclaimer
Disclaimer SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These sta
Slide 3: A new path to optimal health
ZIVO Bioscience, Inc. A new path to optimal health We are creating novel drug candidates, food additives and functional ingredients designed to boost immune health in humans and animals ZIVO Bioscience, Inc. | Ticker: ZIVO 3
Slide 4: Company Overview
Company Overview ZIVO BIOSCIENCE, INC. – NASDAQ: ZIVO; ZIVOW Biotech Addressing billion-dollar global animal health issues. Global food supply. Human immune health. Not just science, but IMPACT. The promise of global solutions for global problems. Biotech/Pharma Agtech/Nutrition Immune modulators to
Slide 5: Investment Highlights
Investment Highlights Potential revenue from multiple income streams. Out-license IP and sell bioproducts. Billion-dollar Biotech & Agtech market verticals span the globe. Small company. Big science. EXPERIENCED INTELLECTUAL ADVANCED EXPANDING MANAGEMENT PROPERTY AGTECH PLATFORM BIOTECH PIPELINE 85+
Slide 6: What do all these global health issues have in common?
What do all these global health issues have in common? Drug-resistant pathogens Autoimmune Disorders Sepsis/Toxic Shock Poultry Coccidiosis Antibiotic residues in dairy products e.Coli contamination Antibiotic-laced meat Bovine Mastitis Type 1 Diabetes Arthritis Multiple Sclerosis Necrotic enteritis
Slide 7: They begin and end with the Immune System
What do all these global health issues have in common? Drug-resistant pathogens Autoimmune Disorders Sepsis/Toxic Shock Poultry Coccidiosis Antibiotic residues in dairy products e.Coli contamination Antibiotic-laced meat Bovine Mastitis They begin and Type 1 Diabetes Arthritis end with the Necrotic
Slide 8: Billions spent on therapeutics, medicines, additives, ingredients
Billions spent on therapeutics, medicines, additives, ingredients Human Market Annualized World Population 1700 C.E. to 2050 C.E. In Billions Antibiotics $40.0B (2020) 12 Eubiotics $37.9B (2019) 10 Autoimmune $110.0B (2017) 8 Antidiabetic $48.8B (2018) 6 4 Immune-related and infectious diseases repr
Slide 9: Billions spent on therapeutics, medicines, additives, ingredients
Billions spent on therapeutics, medicines, additives, ingredients Animal Health Market Antimicrobial Drugs for Livestock 2018 US - Only Vaccines $9.2B (2020) Export** Phytogenics $753.0M (2020) Not independently reported (NIR) Tetracyclines Eubiotics $3.9B (2019) Sulfas $4.1 Billion Penicillins Comp
Slide 10: Billions spent on therapeutics, medicines, additives, ingredients
Billions spent on therapeutics, medicines, additives, ingredients Poultry Market Annualized Vaccines $2.0B (2018) Phytogenics $323.0M* (2020) Eubiotics $1.3B (2019) * Assumes the poultry segment of the overall phytogenics market is approximately 43% Our global food supply is reliant on antimicrobial
Slide 11: A two-tiered platform for human and animal immune health
A two-tiered platform for human and animal immune health Immune health touches all aspects of life Pharma - Biotech Biotech Biotechnology Molecules Patent-pending immune modulator candidate may create a Compounds Complexes new class of therapeutics or immune products Potential impact in multibil
Slide 12: ZIVO Biotech In Vitro Studies
ZIVO Biotech In Vitro Studies Toll-Like Receptor 4 (TLR4) Biotech Molecules Biotechnology Compounds Complexes Immune Cell Membrane ZIVO is developing Bacteria product candidates ZIVO Immune designed to help regulate Modulator the healthy response of immune cell receptors to invading pathogens, traum
Slide 13: ZIVO Agriculture Technology Product Claims
ZIVO Agriculture Technology Product Claims Innate Adaptive AgTech Algal Biomass Extracts Basophil B Cell Agricultural Technology Dry Mixes Immune & Metabolic Health T Cell Eosinophil ZIVO-sponsored in vitro and in vivo studies and analyses point toward A promising new superfood Activators Neutroph
Slide 14: ZIVO Accomplishments
ZIVO Accomplishments Q4 2019 – Q1 2021 Biotech Biotechnology Molecules AgTech Algal Biomass Extracts Compounds Agricultural Technology Dry Mixes Complexes Immune Modulating Molecules Product Development Facilities TLR-4 immune modulator candidate Q4 2019 Lab opened in Ft. Myers, FL for cultivati
Slide 15: ZIVO IP Portfolio
ZIVO IP Portfolio ZIVO has also filed national-phase applications in Canada, Mexico, Brazil, EU, Taiwan, China, India, Japan and/or international CTPs for the following: US Patents Issued/Allowed U.S. Patent No. 7,807,622 issued October 5, 2010, “Composition and Use of Phyto-Percolate for Treatment
Slide 16: Business Models & Market Verticals - Biotech
Business Models & Market Verticals Biotech ZIVO intends to license its proprietary molecules or bioproducts and derive near-term revenues from option and licensing fees, to be followed by long-term royalty streams #1 - Poultry Digestive Health #2 - Porcine Immune #3 - Bovine Mastitis #4 - Canine Joi
Slide 17: Business Models & Market Verticals - AgTech
Business Models & Market Verticals AgTech ZIVO plans a global algae production network and derive near-term revenues from distribution fees and licensing fees, followed by long-term distribution and joint-venture revenues Skin Health/Anti-Aging Products Aquaculture Joint/Exertion Recovery Organic Po
Slide 18: Leadership Team
Leadership Team Andrew A. Dahl - President and CEO Harlan L. Miller III, PhD – VP Technology and Global Supply Over 30 years experience in business case development, marketing Dr. Miller is a recognized expert in algal production systems, planning and business development. Mr. Dahl brings Fortune 50
Slide 19: Growth Prospects - Biotech
Growth Prospects ZIVO intends to license its proprietary molecules or bioproducts and look for opportunities Biotech to fully monetize its intellectual property portfolio across multiple applications #5 - Immune Modulation Therapeutic/Medicinal Product Bioproduct in capsule, caplet or bolus form i
Slide 20: Growth Prospects - AgTech
Growth Prospects ZIVO plans a global algae production network and derive revenues from selling biomass and AgTech joint ventures that market formulated products featuring ZIVO natural biomass products #5 Organic Poultry Feed Probiotic Ingredient Comp Dried algal biomass mixed into #4 Food/Beverage
Slide 21: Where ZIVO is Headed – Goals for 2021 and Beyond
Where ZIVO is Headed – Goals for 2021 and Beyond Biotech Biotechnology Molecules AgTech Algal Biomass Extracts Compounds Agricultural Technology Dry Mixes Complexes Poultry Digestive Health Strategic Partnerships & Regional Distributors Prospective licensing or joint development deal Establish r
Slide 22: Thank You!
Thank You! ZIVO Bioscience, Inc. | Ticker: ZIVO
Slide 23: Sourcing Footnote Addendum
Sourcing Footnote Addendum Page in Deck Item Source / Notes 9 Human - Antibiotics - $40B “The global antibiotics market size was valued at USD 40.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028.” https://www.grandviewresearch.com/industry
Slide 24: Sourcing Footnote Addendum
Sourcing Footnote Addendum Page in Deck Item Source / Notes 11 Poultry Phytogenics - Poultry segment of overall phytogenics market is 43% $323.0M 11 Poultry - Eubiotics - $1.6B 4 - $1.3B for poultry was calculated by taking 22.6% (on page 3) of the global eubiotics market of 5.9 billion in 2019 (on